Lancet Article Points to Role for Statin Drugs in Alzheimer's Disease
New Lancet Article Points to Role for Cholesterol and Statin Drugs in Alzheimer's Disease
HASBROUCK HEIGHTS, N.J., December 1, 2005 - A growing body of evidence points to cholesterol as playing an important role in the Alzheimer's disease process according to a comprehensive review article in the most recent issue of The Lancet Neurology ("Cholesterol in Alzheimer's Disease," December, 2005; 4:841-852). According to researchers from the University of British Columbia, a series of recent studies have shown that excess cholesterol in the brain may promote the formation of senile plaques, one of the hallmarks of Alzheimer's disease. As a result, cholesterol-lowering statins have become a focus of Alzheimer's disease research.
The authors reviewed the growing body of preclinical and clinical studies about statins and their possible benefits for the prevention or treatment of Alzheimer's disease and note that, based on the current state of knowledge, it is up to individual clinicians to determine whether and when to recommend the use of statins to prevent AD. For patients with high cholesterol levels, the authors stated that it seemed prudent to use statins to optimize medical care.
The potential use of statins to treat Alzheimer's disease (AD) has been widely reported in the peer-reviewed medical literature, both in terms of clinical data, (such as J Neurol Neurosurg Psychiatry (2005; 76:1624-1629); The Lancet Neurology (2005; 4:521-2); Arch Neurol (2005; 62:1047-51); Neurology (2005; 64:1531-8); Arch Neurol (2005; 62:753-7); J Neurol Sci (2005; 229-230:147-50); Curr Opin Lipid (2005; 16:619-623); Arch Gen Psychiatry (2005; 62:217-24)) and possible mechanisms through which statins may prevent or slow the progression of Alzheimer's disease (such as J Neurosci Res (2005; 82:10-19); J Biol Chem (2005; M505268200); PLoS Med (2005; 2:e18); J Neurosci (2005; 25:299-307)).
Source: Nymox Pharmaceutical Corporation
Posted: December 2005